GO:0046754 viral exocytosis: genes and methods

Viral exocytosis (GO:0046754) is the biological process by which a fully formed virion particle exits the host cell through exocytosis via a host-derived vesicle. This term captures an egress strategy that is distinct from canonical budding or lysis, because the virion is first enclosed in a host membrane compartment and is then released when that compartment fuses with the plasma membrane. The QuickGO definition places the emphasis on the vesicle as the vehicle and on exocytosis as the release mechanism, which makes the term directly relevant to enveloped viruses that exploit secretory and endolysosomal routes [1,7]. The process matters because it sits at the intersection of viral assembly, host membrane trafficking, and immune evasion. For example, ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress, demonstrating that a single viral protein can redirect a host degradative organelle into a release conduit. Similarly, herpes simplex virus diverts CIN85 endosomal cargo for exocytosis to evade antiviral responses, a mechanism that depends on the viral immediate-early protein ICP0. These findings show that viral exocytosis is not a passive leakage event but an actively regulated trafficking outcome. Researchers study GO:0046754 to understand how virions are routed into vesicles, how those vesicles are acidified and transported, and how fusion with the plasma membrane is controlled. Autophagy proteins have been implicated in viral exocytosis and in anti-viral immune responses, indicating that the pathway overlaps with canonical secretory and autophagic machinery [2,4]. Because the pathway can be hijacked by diverse viruses, it is also a candidate target space for host-directed antiviral strategies [1,3,5].

In this article, viral exocytosis (GO:0046754) is defined as the exit of a fully formed virion particle from the host cell by exocytosis via a host vesicle. The key elements of the definition are that the virion is fully formed before release, that a host-derived vesicle is the carrier, and that exocytosis, meaning fusion of that vesicle with the plasma membrane, is the final release step. The synonym viral egress by exocytosis is used interchangeably in the literature [1,7].

Viral exocytosis is important because it determines how efficiently newly assembled virions leave an infected cell and therefore how quickly an infection can spread to neighboring cells. The pathway is mechanistically distinct from other egress modes and depends on host vesicle trafficking, lysosomal function, and membrane fusion, which makes it a rich source of host-directed antiviral targets [1,3,5]. Because autophagy proteins participate in viral exocytosis and in anti-viral immune responses, the pathway also informs how cells balance proviral secretion against antiviral defense [2,4].

The following genes and proteins have been experimentally linked to viral exocytosis or to the vesicle trafficking steps that define GO:0046754.

Viral exocytosis is regulated at multiple levels. Vesicle acidification is a control point, as shown by progranulin-driven lysosomal acidification facilitating exocytosis of PHEV-hijacked lysosomes for viral release. Cargo sorting is regulated through endosomal adaptors such as CIN85, which herpes simplex virus diverts for exocytosis to evade antiviral responses. Autophagy-related proteins participate in viral exocytosis and in anti-viral immune responses, indicating that autophagic signaling can modulate the pathway [2,4]. Viral accessory proteins such as SARS-CoV-2 ORF3a act as dedicated regulators that promote lysosomal exocytosis-mediated egress. Together, these layers of regulation determine whether a virion is retained, degraded, or released.

SARS-CoV-2 ORF3a promotes lysosomal exocytosis-mediated viral egress, directly connecting GO:0046754 to COVID-19 pathogenesis and to the efficiency of viral spread from infected cells. Because ORF3a is a viral accessory protein, this mechanism also represents a potential target for host-directed or virus-directed interventions.

Herpes simplex virus diverts CIN85 endosomal cargo for exocytosis to evade antiviral responses, a novel role for the viral immediate-early protein ICP0. This links viral exocytosis to the failure of early antiviral defenses and to the establishment of productive HSV infection.

Progranulin-driven lysosomal acidification facilitates exocytosis of PHEV-hijacked lysosomes for viral release, showing that lysosomal physiology controls egress of a neurotropic virus. This connects GO:0046754 to lysosome-dependent release mechanisms that may be relevant to neurological disease.

Autophagy proteins participate in viral exocytosis and in anti-viral immune responses, indicating that the pathway is embedded in host defense and can be modulated by immune signaling [2,4]. This has implications for understanding how autophagy-modulating therapies might influence viral release [2,4].

Viral exocytosis is measured by quantifying infectious virions or viral genomes released into the supernatant after infection. Because the pathway requires vesicle fusion, release assays are often paired with inhibitors of lysosomal acidification or exocytosis to confirm dependence on GO:0046754 [1,5].

Fluorescence imaging of virion-containing vesicles, using markers such as LAMP1 or LC3, allows researchers to visualize the host vesicle that carries the virion. Co-localization of viral proteins with lysosomal or endosomal markers supports a role for exocytosis rather than direct budding [1,3,5].

CRISPR knockout, point mutation, and overexpression models are used to test whether a candidate host or viral gene is required for viral exocytosis. For example, ORF3a knockout or mutation reduces lysosomal exocytosis-mediated egress, while CIN85 perturbation affects HSV cargo diversion [1,3].

Proteomic analysis of vesicle fractions and endosomal cargo can identify proteins recruited to virion-containing compartments. Such approaches help define the molecular composition of the host vesicle used in GO:0046754 and can reveal cargo adaptors such as CIN85 [3,7].

Researchers studying viral exocytosis-related genes often need to determine whether a candidate gene is causally involved in virion release or merely correlated with infection. Establishing causality requires precise, reproducible perturbation of host and viral genomes, followed by quantitative egress assays that distinguish exocytosis from other release modes [1,3,5].

GO:0046754 viral exocytosis defines a vesicle-dependent egress route in which fully formed virions are released from the host cell by exocytosis. Experimental evidence from SARS-CoV-2, herpes simplex virus, and PHEV shows that viral proteins and host trafficking factors such as ORF3a, CIN85, ICP0, and progranulin control this process, and that autophagy-related machinery intersects with it [1,2,3,4,5]. Because the pathway is essential for viral spread and is intertwined with immune evasion, it remains a high-value area for host-directed antiviral research. Studying viral exocytosis requires precise perturbation of candidate genes and quantitative assays that distinguish exocytosis from other release modes. CRISPR knockout, point-mutation, knock-in, overexpression, and library screening approaches provide the causal evidence needed to move from correlation to mechanism in this pathway [1,3,5].